期刊
CLINICAL & EXPERIMENTAL METASTASIS
卷 38, 期 3, 页码 295-303出版社
SPRINGER
DOI: 10.1007/s10585-021-10085-z
关键词
Peritoneal neoplasms; Lung neoplasms; Real world data; Neoplasm metastasis; Epidemiology
类别
Peritoneal metastases from lung cancer are rare, and this study found that factors such as age, tumor stage, nodal stage, tumor morphology, and the presence of systemic metastases are associated with their occurrence. Patients with PM had a median overall survival of 2.5 months, and factors like age, sex, tumor stage, nodal stage, systemic treatment, and systemic metastases were associated with poorer survival outcomes.
Peritoneal metastases (PM) from lung cancer are rare and it is unknown how they affect the prognosis of patients with lung cancer. This population-based study aimed to assess the incidence, associated factors, treatment and prognosis of PM from lung cancer. Data from the Netherlands Cancer Registry were used. All patients diagnosed with lung cancer between 2008 and 2018 were included. Logistic regression analysis was performed to identify factors associated with the presence of PM. Cox regression analysis was performed to identify factors associated with the overall survival (OS) of patients with PM. Between 2008 and 2018, 129,651 patients were diagnosed with lung cancer, of whom 2533 (2.0%) patients were diagnosed with PM. The European Standardized Rate of PM increased significantly from 0.6 in 2008 to 1.4 in 2018 (p < 0.001). Age between 50 and 74 years, T3-4 tumour stage, N2-3 nodal stage, tumour morphology of a small cell lung cancer or adenocarcinoma, and the presence of systemic metastases were associated with the presence of PM. The median OS of patients with PM was 2.5 months. Older age, male sex, T3-4 tumour stage, N2-3 nodal stage, not receiving systemic treatment, and the presence of systemic metastases were associated with a worse OS. Synchronous PM were diagnosed in 2.0% of patients with lung cancer and resulted in a very poor survival.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据